Anne Pawlak, DO
Neurology · Traverse City, MINPI 1891784484
Payments from drug & device makers
Across 335 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$948
- UCB, Inc.$770
- CSL Behring$434
- Avanir Pharmaceuticals, Inc.$401
- MDD US Operations, LLC$348
- Amgen$320
- plus $4K from 29 others
What the payments were for
- Speaking & faculty fees$1011%
- Food & beverage$6,61098%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 49 | $948 |
| UCB, Inc. | 32 | $770 |
| CSL Behring | 20 | $434 |
| Avanir Pharmaceuticals, Inc. | 30 | $401 |
| MDD US Operations, LLC | 10 | $348 |
| Amgen | 21 | $320 |
| Otsuka America Pharmaceutical, Inc. | 20 | $313 |
| Teva Pharmaceuticals USA, Inc. | 17 | $295 |
| Novartis | 17 | $289 |
| Alnylam Pharmaceuticals Inc. | 7 | $275 |
| Lilly USA, LLC | 13 | $255 |
| Acorda Therapeutics, Inc | 8 | $199 |
| Genentech USA, Inc. | 15 | $197 |
| AstraZeneca | 6 | $192 |
| Sumitomo Pharma America, Inc. | 11 | $170 |
| AbbVie | 7 | $169 |
| Grifols USA, LLC | 2 | $168 |
| Alkermes, Inc. | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $121 |
| EMD Serono, Inc. | 7 | $109 |
| Sunovion Pharmaceuticals Inc. | 8 | $95 |
| Vertical Pharmaceuticals, LLC | 5 | $78 |
| Bristol Myers Squibb | 3 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $64 |
| Acadia Pharmaceuticals Inc | 4 | $58 |
| Pfizer | 4 | $57 |
| TG Therapeutics, Inc. | 2 | $38 |
| Catalyst Pharmaceuticals, Inc. | 2 | $33 |
| Adamas Pharmaceuticals, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Sanofi | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Zogenix Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- Briviact$242
- Gamunex-C$145
- ARISTADA INITIO$125
- APOKYN$123
- NURTEC ODT$121
- ONPATTRO$117
- MYOBLOC$112
- AUSTEDO$110
How this compares
$6,753 in reported general payments places this provider in the 70th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 28 | $181,681 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $180,595 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $180,145 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 17 | $166,727 |
| CopaxoneGlatiramer Acetate | 27 | $148,745 |
| BetaseronInterferon Beta-1b | 16 | $148,256 |
| AubagioTeriflunomide | 12 | $84,456 |
| Teriflunomide | 20 | $69,201 |
| Nurtec OdtRimegepant Sulfate | 17 | $26,953 |
| LamictalLamotrigine | 13 | $26,211 |
| BriviactBrivaracetam | 15 | $21,887 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,479 |
| Levetiracetam | 182 | $7,606 |
| Oxcarbazepine | 63 | $7,257 |
| Memantine Hcl | 233 | $6,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen, Hizentra | $434 | $362,27641 claims |
| Grifols USA, LLCGamunex-C | $168 | $180,14526 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $295 | $148,74527 claims |
| SanofiAubagio | $19 | $84,45612 claims |
| PfizerNurtec Odt, Dilantin | $57 | $30,40633 claims |
| UCB, Inc.Briviact | $770 | $21,88715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 652 neurology providers in Michigan.
Other neurology in Traverse City
- Cornelius RobensTraverse City$203K
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.